CL2016001098A1 - Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales - Google Patents

Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales

Info

Publication number
CL2016001098A1
CL2016001098A1 CL2016001098A CL2016001098A CL2016001098A1 CL 2016001098 A1 CL2016001098 A1 CL 2016001098A1 CL 2016001098 A CL2016001098 A CL 2016001098A CL 2016001098 A CL2016001098 A CL 2016001098A CL 2016001098 A1 CL2016001098 A1 CL 2016001098A1
Authority
CL
Chile
Prior art keywords
derivatives
treatment
cysteamine
mitochondrial diseases
mitochondrial
Prior art date
Application number
CL2016001098A
Other languages
English (en)
Inventor
Patrice Rioux
Todd C Zankel
Original Assignee
Raptor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raptor Pharmaceuticals Inc filed Critical Raptor Pharmaceuticals Inc
Publication of CL2016001098A1 publication Critical patent/CL2016001098A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

METODO DE TRATAMIENTO DE UN TRASTORNO MITOCONDRIAL HEREDADO O ADQUIRIDO QUE COMPRENDE ADMINISRAR CISTEAMINA O CISTAMINA O SUS DERIVADOS.
CL2016001098A 2013-11-06 2016-05-06 Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales CL2016001098A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361900772P 2013-11-06 2013-11-06

Publications (1)

Publication Number Publication Date
CL2016001098A1 true CL2016001098A1 (es) 2016-12-23

Family

ID=53007221

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001098A CL2016001098A1 (es) 2013-11-06 2016-05-06 Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales

Country Status (13)

Country Link
US (1) US20150125526A1 (es)
EP (1) EP3065725A4 (es)
JP (1) JP2016540827A (es)
KR (1) KR20160070154A (es)
CN (1) CN105873579A (es)
CA (1) CA2928442A1 (es)
CL (1) CL2016001098A1 (es)
EA (1) EA201690936A1 (es)
IL (1) IL245231A0 (es)
MX (1) MX2016005858A (es)
PH (1) PH12016500842A1 (es)
TW (1) TW201605434A (es)
WO (1) WO2015069888A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108289867A (zh) * 2015-07-02 2018-07-17 地平线孤儿病有限责任公司 Ado-抗性的半胱胺类似物和其用途
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
WO2018013811A1 (en) * 2016-07-14 2018-01-18 The Regents Of The University Of California Diagnostic and methods of treatment for chronic fatigue syndrome and autism spectrum disorders
US11662339B1 (en) * 2016-11-02 2023-05-30 Kyoto University Efficacy determination markers in disease treatment by PD-1 signal inhibitor
GB2581362A (en) 2019-02-14 2020-08-19 Univ Of Sunderland Chemical synthesis
WO2022249942A1 (ja) * 2021-05-24 2022-12-01 国立大学法人岩手大学 網膜の神経細胞の保護剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004612A2 (en) * 2000-07-07 2002-01-17 Incyte Genomics, Inc. Drug metabolizing enzymes
WO2011069002A1 (en) * 2009-12-02 2011-06-09 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
US20120309785A1 (en) * 2010-12-03 2012-12-06 Bill Piu Chan Use of Cysteamine in Treating Parkinson's Disease

Also Published As

Publication number Publication date
CN105873579A (zh) 2016-08-17
EP3065725A2 (en) 2016-09-14
EP3065725A4 (en) 2017-06-14
JP2016540827A (ja) 2016-12-28
US20150125526A1 (en) 2015-05-07
EA201690936A1 (ru) 2016-08-31
IL245231A0 (en) 2016-06-30
WO2015069888A2 (en) 2015-05-14
PH12016500842A1 (en) 2016-07-04
TW201605434A (zh) 2016-02-16
WO2015069888A3 (en) 2015-11-12
MX2016005858A (es) 2016-08-11
CA2928442A1 (en) 2015-05-14
KR20160070154A (ko) 2016-06-17

Similar Documents

Publication Publication Date Title
ECSP24031979A (es) Compuestos terapéuticamente activos y sus métodos de uso
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
BR112018010464A8 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
CL2016001098A1 (es) Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales
NI201600071A (es) Compuestos de inhibidor de autotaxina
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016000392A1 (es) Análogos de cortistatina para el tratamiento de enfermedades con componente inflamatorio y/o inmune
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
CL2017001046A1 (es) Inhibidoes del bromodominio
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
BR112016010271A2 (pt) Anticorpo, composição farmacêutica, método de tratamento, uso de um anticorpo e combinação
CL2016000042A1 (es) Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
DK3463436T3 (da) Vaccine i kombination med en immuncheckpoint-hæmmer til anvendelse i cancerbehandling
CL2016002779A1 (es) Composición para el cuidado de la piel
CL2015001936A1 (es) Composición y su uso que sirve para preparar un medicamento útil para tratar enfermedades relacionadas con el factor inducible por hipoxia (hif).
CL2015003585A1 (es) Combinaciones para el tratamiento de cáncer que comprende un inhibidor de la quinasa mps-1 y un inhibidor de la mitosis
CL2016000396A1 (es) Tratamiento contra el mieloma múltiple
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
ES1165083Y (es) Dispositivo para el posicionamiento de pacientes en tratamientos de radioterapia